Showing results (111-120 of 158) with videos related to

Sort By:
Pageof 16
Biochemical Pharmacology|January 8, 2013
Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicityKumiko Nishihara, Satohiro Masuda, Haruka Shinke, et al.
Digestive Diseases and Sciences|March 10, 2009
Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experienceHiroto Egawa, Kaoru Taira, Satoshi Teramukai, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinomaKojiro Hata, Kimitaka Suetsugu, Nobuaki Egashira, et al.
The Pediatric Infectious Disease Journal|December 16, 2016
Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety AnalysisTakaaki Yamada, Toshio Kubota, Mahoro Yonezawa, et al.
Pharmacogenetics and Genomics|June 10, 2014
Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantationMiwa Uesugi, Mio Kikuchi, Haruka Shinke, et al.
Drug Metabolism and Pharmacokinetics|August 20, 2013
Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patientsKeiko Hosohata, Miwa Uesugi, Sachiyo Hashi, et al.
International Journal of Hematology|November 9, 2016
Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantationKimitaka Suetsugu, Hiroaki Ikesue, Toshihiro Miyamoto, et al.
Pharmaceutical Research|October 26, 2005
Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritisYuji Sakurai, Hideyuki Motohashi, Ken Ogasawara, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2012
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Satohiro Masuda, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodiesYasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi, et al.
Pageof 16